Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer’s treatment Leqembi, saw growth.